Drug Trial Radar · NCT05974410
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- AVM Biotechnology IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2023
Design
- Study type
- Expanded access
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.
Conditions
- Glioblastoma
- Squamous Cell Carcinoma
- Hodgkin Lymphoma
- Non-hodgkin Lymphoma
- Breast Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Acute Leukemia
- Pancreatic Cancer
- Spindle Cell Sarcoma
- Cancer
- Tumor, Solid
- Tumor, Brain
- Esophageal Andeocarcinoma
- Mixed Phenotype AML
- Desmoplastic Round Cell Sarcoma
Interventions
AVM0703Drug
small molecule immunomodulatory drug
HydrocortisoneDrug
physiologic circadian glucocorticoid
Proton pump inhibitorDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.